312 related articles for article (PubMed ID: 34049825)
1. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
5. Temporal and Spatial Epigenome Editing Allows Precise Gene Regulation in Mammalian Cells.
Kuscu C; Mammadov R; Czikora A; Unlu H; Tufan T; Fischer NL; Arslan S; Bekiranov S; Kanemaki M; Adli M
J Mol Biol; 2019 Jan; 431(1):111-121. PubMed ID: 30098338
[TBL] [Abstract][Full Text] [Related]
6. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
[TBL] [Abstract][Full Text] [Related]
7. Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator.
Villamizar O; Waters SA; Scott T; Saayman S; Grepo N; Urak R; Davis A; Jaffe A; Morris KV
Mol Ther; 2019 Oct; 27(10):1737-1748. PubMed ID: 31383454
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-based epigenome editing: mechanisms and applications.
Fadul SM; Arshad A; Mehmood R
Epigenomics; 2023 Nov; 15(21):1137-1155. PubMed ID: 37990877
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing.
Moses C; Hodgetts SI; Nugent F; Ben-Ary G; Park KK; Blancafort P; Harvey AR
Sci Rep; 2020 Jul; 10(1):11393. PubMed ID: 32647121
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
Gemberling MP; Siklenka K; Rodriguez E; Tonn-Eisinger KR; Barrera A; Liu F; Kantor A; Li L; Cigliola V; Hazlett MF; Williams CA; Bartelt LC; Madigan VJ; Bodle JC; Daniels H; Rouse DC; Hilton IB; Asokan A; Ciofani M; Poss KD; Reddy TE; West AE; Gersbach CA
Nat Methods; 2021 Aug; 18(8):965-974. PubMed ID: 34341582
[TBL] [Abstract][Full Text] [Related]
11. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
12. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
13. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
Guerra-Resendez RS; Hilton IB
Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
[TBL] [Abstract][Full Text] [Related]
14. P.F508del editing in cells from cystic fibrosis patients.
Smirnikhina SA; Kondrateva EV; Adilgereeva EP; Anuchina AA; Zaynitdinova MI; Slesarenko YS; Ershova AS; Ustinov KD; Yasinovsky MI; Amelina EL; Voronina ES; Yakushina VD; Tabakov VY; Lavrov AV
PLoS One; 2020; 15(11):e0242094. PubMed ID: 33175893
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Mediated Transcriptional Repression in Toxoplasma gondii.
Markus BM; Boydston EA; Lourido S
mSphere; 2021 Oct; 6(5):e0047421. PubMed ID: 34643425
[TBL] [Abstract][Full Text] [Related]
16.
Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
[TBL] [Abstract][Full Text] [Related]
17. Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells.
Bulcaen M; Kortleven P; Liu RB; Maule G; Dreano E; Kelly M; Ensinck MM; Thierie S; Smits M; Ciciani M; Hatton A; Chevalier B; Ramalho AS; Casadevall I Solvas X; Debyser Z; Vermeulen F; Gijsbers R; Sermet-Gaudelus I; Cereseto A; Carlon MS
Cell Rep Med; 2024 May; 5(5):101544. PubMed ID: 38697102
[TBL] [Abstract][Full Text] [Related]
18. Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA.
Sanz DJ; Hollywood JA; Scallan MF; Harrison PT
PLoS One; 2017; 12(9):e0184009. PubMed ID: 28863137
[TBL] [Abstract][Full Text] [Related]
19. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Hilton IB; D'Ippolito AM; Vockley CM; Thakore PI; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2015 May; 33(5):510-7. PubMed ID: 25849900
[TBL] [Abstract][Full Text] [Related]
20. Investigating REPAIRv2 as a Tool to Edit
Melfi R; Cancemi P; Chiavetta R; Barra V; Lentini L; Di Leonardo A
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
